Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-11. Numbers and descriptions here follow the published literature rather than marketing material.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
Adenomatous polyposis coli protein 2 is a protein that in humans is encoded by the APC2 gene. This is a dual-functional protein which is especially prevalant in the developing brain, and involved in cell signaling (specifically Wnt signaling) and stabilizing the cytoskeleton. Frizzled receptors are a type of cell receptor involved in a variety of functions including embryonic development and cell proliferation. These receptors trigger a cascade of reactions called the Wnt signaling pathway that eventually leads to interaction with the DNA via the protein beta-catenin, which affects which proteins get produced by the cell. The APC2 protein promotes the formation of a protein complex which is involved in breaking down the protein beta-catenin. The APC2 protein stabilizes microtubules, which are part of the cell cytoskeleton. It may also be involved in the regulation of actin fibers my means of GTPase activation (specifically the Rho family).
A significant amount of zirconium is formed by the fission process; some of this consists of short-lived radionuclides (95Zr and 97Zr which decay to molybdenum), while almost 10% of the fission products mixture after years of decay consists of five stable or nearly stable isotopes of zirconium plus 93Zr with a halflife of 1.53 million years which is one of the 7 major long-lived fission products. Zirconium is commonly used in cladding of fuel rods due to its low neutron cross section. However, a small share of this zirconium does capture neutrons and contributes to the overall inventory of radioactive zirconium isotopes. Zircalloy cladding is not commonly reused and neither is fission product zirconium, which could be used in cladding as its relatively weak radioactivity would be of no major concern inside a nuclear reactor. Despite its high yield and long live, Zr-93 is generally not deemed to be of major concern as it is not chemically mobile and emits little radiation. In PUREX plants the zirconium (regardless of source or isotope) sometimes forms a third phase which can be a disturbance in the plant. The third phase is the term in solvent extraction given to a third layer (such as foam and/or emulsion) which forms from the two layers in the solvent extraction process. The zirconium forms the third phase by forming small particles which stabilise the emulsion which is the third phase. Zirconium-90 mostly forms by successive beta decays out of strontium-90.
==== State space search ==== State space search searches through a tree of possible states to try to find a goal state. For example, planning algorithms search through trees of goals and subgoals, attempting to find a path to a target goal, a process called means-ends analysis. Simple exhaustive searches are rarely sufficient for most real-world problems: the search space (the number of places to search) quickly grows to astronomical numbers. The result is a search that is too slow or never completes. "Heuristics" or "rules of thumb" can help prioritise choices that are more likely to reach a goal. Adversarial search is used for game-playing programs, such as chess or Go. It searches through a tree of possible moves and countermoves, looking for a winning position.
The British historian Richard Overy wrote the huge demands of the Four Year Plan "...could not be fully met by a policy of import substitution and industrial rationalisation", thus leading Hitler to decide in November 1937 that to stay ahead in the arms race with the other powers that Germany had to seize Czechoslovakia in the near-future. At the Hossbach conference on 5 November 1937, Hitler announced that seizing Czechoslovakia would increase the supply of food under German control, which in turn would lessen the need to import food, thereby freeing up more foreign exchange to import raw materials necessary for the Four Year Plan's targets. The Hossbach conference was largely taken up with an extended discussion about the necessity of bringing areas adjunct to Germany under German economic control, by force if necessary, as Hitler argued that this was the best way to win the arms race. Hitler stated: "areas producing raw materials can be more usefully sought in Europe, in immediate proximity to the Reich". Overy wrote about Hitler's attitude to the Reich's economic problems that: "He simply saw war instrumentally, as the Japanese had done in Manchuria, as a way to expand the German resource base and to secure it against other powers". At the time, Czechoslovakia had Europe's 7th largest economy, and easily the most modern, developed, and industrialized economy in Eastern Europe.
== Autoproteolytic activity == The use of high-resolution ion-mobility mass spectrometry (IMS-MS) on HPLC-purified alpha-synuclein in vitro has shown alpha-synuclein to be autoproteolytic (self-proteolytic), generating a variety of small molecular weight fragments upon incubation. The 14.46 kDa protein was found to generate numerous smaller fragments, including 12.16 kDa (amino acids 14–133) and 10.44 kDa (40–140) fragments formed through C- and N-terminal truncation and a 7.27 kDa C-terminal fragment (72–140). The 7.27 kDa fragment, which contains the majority of the NAC region, aggregated considerably faster than full-length alpha-synuclein. It is possible that these autoproteolytic products play a role as intermediates or cofactors in the aggregation of alpha-synuclein in vivo.
Sources: en.wikipedia.org
An RNA copy of the coding strand of a gene which is translated into a polypeptide chain at a ribosome; Transfer RNA (tRNA) Transfers specific amino acids to growing polypeptide chains at the ribosomal site of protein synthesis during translation; Ribosomal RNA (rRNA) Incorporates into ribosomes; Micro RNA (miRNA) Regulates gene activity; and, RNA silencing Catalytic RNA (ribozyme) Functions as an enzymatically active RNA molecule. RNA polymerase is essential to life, and is found in all living organisms and many viruses. Depending on the organism, a RNA polymerase can be a protein complex (multi-subunit RNAP) or only consist of one subunit (single-subunit RNAP, ssRNAP), each representing an independent lineage. The former is found in bacteria, archaea, and eukaryotes alike, sharing a similar core structure and mechanism. The latter is found in phages as well as eukaryotic chloroplasts and mitochondria, and is related to modern DNA polymerases. Eukaryotic and archaeal RNAPs have more subunits than bacterial ones do, and are controlled differently. Bacteria and archaea only have one RNA polymerase. Eukaryotes have multiple types of nuclear RNAP, each responsible for synthesis of a distinct subset of RNA:
== Education == In 1978, Schleip became Germany's first certified rolfer at the Rolf Institute and in 1983 became a Certified Advanced Rolfer in the field of Structural Integration. Schleip graduated with a degree in psychology from Heidelberg University in 1980. From 1984 to 1987 he trained as a Feldenkrais teacher and became a Certified Feldenkrais Practitioner in the field of Sensorimotor Facilitation from the International Feldenkrais Guild in 1987. In 2006, he earned his doctorate in human biology from the University of Ulm. That year he received the "Vladimir Janda Prize for Musculoskeletal Medicine" for research he performed with Werner Klingler. In 2023, he was appointed to a research professorship in the department for Health & Psychology for the university by the Diploma University of Applied Sciences.
Nearly all cell membranes in animals, plants and fungi maintain a voltage difference between the exterior and interior of the cell, called the membrane potential. A typical voltage across an animal cell membrane is −70 mV. This means that the interior of the cell has a negative voltage relative to the exterior. In most types of cells, the membrane potential usually stays fairly constant. Some types of cells, however, are electrically active in the sense that their voltages fluctuate over time. In some types of electrically active cells, including neurons and muscle cells, the voltage fluctuations frequently take the form of a rapid upward (positive) spike followed by a rapid fall. These up-and-down cycles are known as action potentials. Their duration varies considerably with the type of cell. In mammalian neurons, the entire up-and-down cycle takes only a few thousandths of a second, while in plant cells, an action potential may last as long as several seconds. The electrical properties of a cell are determined by the structure of its membrane. A cell membrane consists of a lipid bilayer of molecules in which larger protein molecules are embedded. The lipid bilayer is highly resistant to movement of electrically charged ions, so it functions as an insulator. The large membrane-embedded proteins, in contrast, provide channels through which ions can pass across the membrane. Action potentials are driven by channel proteins whose configuration switches between closed and open states as a function of the voltage difference between the interior and exterior of the cell.
=== Alanine === Alanine is produced by the transamination of one molecule of pyruvate using two alternate steps: 1) conversion of glutamate to α-ketoglutarate using a glutamate-alanine transaminase, and 2) conversion of valine to α-ketoisovalerate via Transaminase C. Not much is known about the regulation of alanine synthesis. The only definite method is the bacterium's ability to repress Transaminase C activity by either valine or leucine (see ilvEDA operon). Other than that, alanine biosynthesis does not seem to be regulated.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.